Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-28T09:29:24.327Z Has data issue: false hasContentIssue false
  • English
  • Français

Economic impact of recurrent respiratory papillomas in a UK adult population

Published online by Cambridge University Press:  18 May 2016

A Harrison ,
J Montgomery  and
F B Macgregor
A Harrison*
Affiliation:
Department of Otolaryngology, North Manchester General Hospital, Pennine Acute Trust, UK
J Montgomery
Affiliation:
Department of Otolaryngology, Queen Elizabeth University Hospital, Glasgow, Scotland, UK
F B Macgregor
Affiliation:
Department of Otolaryngology, Gartnavel General Hospital, Glasgow, Scotland, UK
*
Address for correspondence: Miss Anna Harrison, Department of Otolaryngology, North Manchester General Hospital, Delaunays Road, Manchester M8 5RB, UK Fax: 0161 778 3646 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To calculate the financial burden of recurrent respiratory papilloma. This study is UK-based, where up until now no financial estimates have been calculated for this group of patients.

Background:

Recurrent respiratory papilloma is caused by the human papilloma virus (subtypes 6 and 11). The burden for the patient and the healthcare system is significant given the recurrent nature of the disease.

Methods:

Data were collected, using a questionnaire completed during routine clinical follow up, from a single centre managing recurrent respiratory papilloma in Glasgow, Scotland. Cost information was sourced from the Scottish Government's Information Services Division.

Results:

Fourteen patients with active recurrent respiratory papilloma between 2013 and 2014 were identified. The direct measurable cost to NHS Greater Glasgow and Clyde amounted to £107 478.

Conclusion:

Recurrent respiratory papilloma is a benign condition, but the financial implications of diagnosis are significant. Recurrent respiratory papilloma has a natural history of relapse and remission, and patients may require healthcare input over a period of several years.

Keywords

PapillomaHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Recurrent Respiratory PapillomatosisCost Of Illness
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 130 , Issue 7 , July 2016 , pp. 645 - 649
Copyright
Copyright © JLO (1984) Limited 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Goon, P, Sonnex, C, Jani, P, Stanley, M, Sudhoff, H.Recurrent respiratory papillomatosis: an overview of current thinking and treatment. Eur Arch Otolaryngol 2008;265:147–51CrossRefGoogle ScholarPubMed
2Larson, DA, Derkay, CS.Epidemiology of recurrent respiratory papillomatosis. APMIS 2010;118:450–4CrossRefGoogle ScholarPubMed
3Hill, DS, Akhtar, S, Corroll, A, Croft, CB.Quality of life issues in recurrent respiratory papillomatosis. Clin Otolaryngol Allied Sci 2000;25:153–60CrossRefGoogle ScholarPubMed
4Carifi, M, Napolitano, D, Morandi, M, Dall'Olio, D.Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag 2015;11:731–8CrossRefGoogle ScholarPubMed
5Loizou, C, Laurell, G, Lindquist, D, Olofsson, K.Voice and quality of life in patients with recurrent respiratory papillomatosis in a northern Sweden cohort. Acta Otolaryngol 2014;134:401–6CrossRefGoogle Scholar
6Derkay, CS, Volsky, PG, Rosen, CA, Pransky, SM, McMurray, JS, Chadha, NK.Current use of intralesional cidofovir for recurrent respiratory papillomatosis. Laryngoscope 2013;123:705–12CrossRefGoogle ScholarPubMed
7Healy, GB, Gelber, RD, Trowbridge, AL, Grundfast, KM, Ruben, RJ, Price, KN.Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med 1988;319:401–7CrossRefGoogle ScholarPubMed
8Leventhal, BG, Kashima, HK, Mounts, P, Thurmond, L, Chapman, S, Buckley, S et al. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1. Papilloma Study Group. N Engl J Med 1991;325:613–17CrossRefGoogle ScholarPubMed
9Gerein, V, Rastorguev, E, Gerein, J, Jecker, P, Pfister, H.Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005;114:463–71CrossRefGoogle ScholarPubMed
10Endres, DR, Bauman, NM, Burke, D, Smith, RJ.Acyclovir in the treatment of recurrent respiratory papillomatosis. A pilot study. Ann Otol Rhinol Laryngol 1994;103:301–5CrossRefGoogle ScholarPubMed
11Lippman, SM, Donovan, DT, Frankenthaler, RA, Weber, RS, Earley, CL, Hong, WK et al. 13-Cis-retinoic acid plus interferon-alpha 2a in recurrent respiratory papillomatosis. J Natl Cancer Inst 1994;86:859–61CrossRefGoogle ScholarPubMed
12Lu, B, Kumar, A, Castellsaqué, X, Giuliano, AR.Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis. BMC Infect Dis 2011;11:13CrossRefGoogle Scholar
13ISD Scotland. Acute Surgical Speciality Costs. In: http://www.isdscotland.org/Health-Topics/Finance/Costs/Detailed-Tables/Speciality-Costs/Acute-Surgical.asp [25 November 2015]Google Scholar
14Medicines Complete. Human Papilloma Vaccines. In: https://www.medicinescomplete.com/mc/bnf/current/DMD10880211000001104.htm?q=gardasil&t=search&ss=text&p=1#DMD10880211000001104 [26 November 2015]Google Scholar
15Pasquale, K, Wiatrak, B, Woolley, A, Lewis, L.Microdebrider versus CO2 laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope 2003;113:139–43CrossRefGoogle ScholarPubMed
16Cohen, SM, Kim, J, Roy, N, Asche, C, Courey, M.Direct health care costs of laryngeal diseases and disorders. Laryngoscope 2012;122:1582–8CrossRefGoogle ScholarPubMed
17Blomberg, M, Dehlendorff, C, Munk, C, Kjaer, SK.Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013;57:929–34CrossRefGoogle ScholarPubMed
18Langley, PC, White, DJ, Drake, SM.The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004;15:501–8CrossRefGoogle Scholar